• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

NLA 2025: GLP-1 Therapies May Impact Cardiovascular and Renal Health Independent of Weight Loss

by MM360 Staff | May 31, 2025 | Myeloma News

Source: Pharmacy Times articles GLP-1 receptor agonists, including semaglutide and tirzepatide, significantly reduce cardiometabolic risk factors such as dyslipidemia, type 2 diabetes, metabolic dysfunction-associated steatohepatitis, obstructive sleep apnea, chronic...

NLA 2025: Novel Therapeutic Approaches Show Promise for Targeted Reduction of Lp(a) in Patients With ASCVD

by MM360 Staff | May 31, 2025 | Myeloma News

Source: Pharmacy Times articles At the 2025 National Lipid Association (NLA) Scientific Sessions, Marlys L. Koschinsky, PhD, FNLA, discusses the role of Lp(a) in cardiovascular risk and the emerging therapies designed to target and lower Lp(a) levels. Read...

ESR1, PIK3CA, and Beyond: Precision Therapy Advances in HR+ Breast Cancer

by MM360 Staff | May 31, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

Updated ASCO-NCODA MIP Standards Emphasize Health Equity, Patient-Centered Care, and Integrated Workflows in Oral Oncolytic Management

by MM360 Staff | May 31, 2025 | Myeloma News

Source: Pharmacy Times articles Gurjyot K. Doshi, MD, discusses key updates to medically integrated pharmacy standards, which reflect the evolving landscape of oral oncolytic therapy. Read More

A simple genomic score to predict progression of multiple myeloma

by MM360 Staff | May 31, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

IVIG Increases Platelet Counts in Pregnant Patients With Severe Thrombocytopenia, With Identifiable Aspects of Response

by MM360 Staff | May 31, 2025 | Myeloma News

Source: Pharmacy Times articles IVIG treatment significantly boosts platelet counts in pregnant people with thrombocytopenia, revealing key predictors for effective response and optimizing clinical decisions. Read More
« Older Entries
Next Entries »

Recent Content

  • Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
  • Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
  • Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
  • (no title)
  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • (no title)
  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT